Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces a pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2011.
Recent trading has been in line with management's expectations. Sales for the six months ended 30 June 2011 were approximately £24.4m, £1.0m ahead of the first half of 2010. As previously reported, sales of DeltacortrilTM / enteric coated prednisolone have been impacted by greater competition, but the promoted portfolios of Dermatology and Oncology continue to grow well, in particular HydromolTM, which has grown 26% compared with the first half of 2010.
Following the acquisition of AnbesolTM and Ashton & ParsonsTM in April 2011 we are pleased with the demand shown for these products in the first two months of ownership.
The Company's interim results are due to be announced on 7 September 2011.
For further information:
Alliance Pharma plc
+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
+ 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Numis Securities Limited
+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney
Notes to editors:
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.